| EPF045 | Analysing the role of stigma and racism in harm reduction policy: a tri-country analysis | E-poster | Availability and access to harm reduction (including OST and NSP) |
| EPC454 | Analysis of HIV case finding and continuity on treatment strategies and outcomes before and during the COVID-19 pandemic: The RISE Nigeria experience | E-poster | Effects of the COVID-19 on HIV epidemiology and prevention |
| EPLBA02 | Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T cell correlates of HIV-1 acquisition risk | E-poster | Cellular immunity; T cell vaccines |
| EPB258 | Analysis of the impact of COVID-19 pandemic on PrEP uptake in Toronto: a retrospective 18-month single-site chart review | E-poster | Impact of COVID-19 on HIV care |
| EPLBB08 | Analytical treatment interruption (ATI) among African women with early ART initiation with or without VRC01 circulating at HIV acquisition: study design and early observations of viral rebound and control | E-poster | Cure interventions |
| PEMOE47 | Analyzing FY 19-21 PEPFAR PrEP uptake focusing on adolescent girls and young women and key populations | Poster exhibition | Optimizing HIV services (prevention, testing and/or treatment) in the COVID-19 era |
| EPD123 | Antecipated stigma and socio barriers to communication between transgender women living with HIV and healthcare providers: a mediation analysis | E-poster | Transgender people |
| EPD269 | Antenatal care; an experience of pregnant women testing HIV positive in Koome Island, Mukono-Uganda | E-poster | Harm reduction |
| PESAB07 | Antenatal systemic inflammation and mortality of children born to mothers with HIV in rural Zimbabwe | Poster exhibition | Biomarkers for the prediction of morbidity and mortality |
| PELBA01 | Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice | Poster exhibition | Gene therapy |